Markets:

Overview

News

Currencies

International

Treasuries

Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

14.19 -0.83 (-5.53%)

Streaming Delayed Price Updated: 12:17 PM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Phathom Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Nasdaq Turns Positive; Crude Oil Moves Higher ↗

August 02, 2022

U.S. stocks pared losses midway through trading, with the S&P 500 and Nasdaq Composite turning higher on Tuesday.

Via Benzinga

Recap: Phathom Pharmaceuticals Q2 Earnings ↗

August 02, 2022

Phathom Pharmaceuticals (NASDAQ:PHAT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

67 Biggest Movers From Yesterday ↗

June 22, 2022

Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

January 18, 2022

Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗

May 31, 2022

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...

Via Benzinga

FDA Accepts Review Of Phathom Pharmaceuticals' NDA For Vonoprazan ↗

May 25, 2022

The Food and Drug Administration (FDA) has accepted for review Phathom Pharmaceuticals’ (NASDAQ: PHAT) New Drug Application (NDA) of its lead drug candidate Vonoprazan for the healing of all grades of...

Via Benzinga

The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine ↗

May 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

81 Biggest Movers From Yesterday ↗

May 18, 2022

Gainers Eos Energy Enterprises, Inc. (NASDAQ: EOSE) shares gained 41.8% to settle at $1.90 on Tuesday. Eos Energy Enterprises recently reported worse-than-expected Q1 EPS and sales results.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 12, 2022

Via Benzinga

Phathom Pharmaceuticals: Q1 Earnings Insights ↗

May 10, 2022

Phathom Pharmaceuticals (NASDAQ:PHAT) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

90 Biggest Movers From Yesterday ↗

May 10, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates ↗

May 01, 2022

The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a...

Via Benzinga

Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference ↗

April 13, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 15, 2022

During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 09, 2022

Gainers Bone Biologics (NASDAQ:BBLG) shar...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 12, 2022

On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen (NASDAQ:BIIB) was the biggest company by market cap to set a...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 28, 2021

Gainers Medigus (NASDAQ:MDGS) shares moved upwards by 12.04% to $1.62 during Thursday's pre-market session. The market value of their outstanding shares is at $38.6...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

January 07, 2022

Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap...

Via Benzinga

30 Stocks Moving in Thursday's Pre-Market Session ↗

October 28, 2021

Gainers InflaRx N.V. (NASDAQ: IFRX) rose 47.9% to $4.23 in pre-market trading. Raymond James upgraded InflaRx from Outperform to Strong Buy and announced a $14 price target....

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 27, 2021

Gainers Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 15.4% to $33.42 during Wednesday's regular session. Trading volume for Nurix Therapeutics's stock...

Via Benzinga

46 Biggest Movers From Yesterday ↗

October 19, 2021

Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial...

Via Benzinga

64 Biggest Movers From Yesterday ↗

October 28, 2021

Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 18, 2021

Gainers Dermata Therapeutics (NASDAQ:DRMA

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 18, 2021

Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 EST, Progenity's stock is trading at a volume of...

Via Benzinga

34 Stocks Moving In Monday's Mid-Day Session ↗

October 18, 2021

Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare....

Via Benzinga

Mid-Morning Market Update: Markets Mostly Lower; Albertsons Tops Q2 Estimates ↗

October 18, 2021

Following the market opening Monday, the Dow traded down 0.32% to 35,182.99 while the NASDAQ rose 0.12% to 14,915.84. The S&P also fell, dropping 0.06% to 4,468.81. The U.S....

Via Benzinga

Topics Stocks

Phathom's Vonoprazan Non-Inferior To Proton Pump Inhibitor For Esophagitis Inflammation ↗

October 18, 2021

Phathom Pharmaceuticals Inc (NASDAQ: PHAT) has announced data from the PHALCON-EE Phase 3 trial evaluating vonoprazan versus lansoprazole for erosive esophagitis (...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.